GEN1286 / Genmab - LARVOL DELTA

Trial to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activity of GEN1286 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=214 | Recruiting | Sponsor: Genmab | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor

Genmab/Pufang Bio: EGFR/cMET dual-antibody ADC starts phase 1/2 clinical trial [Google translation] (vbdata.cn) - "Genmab has launched a Phase 1/2 clinical trial of EGFR/cMET dual-antibody ADC, with plans to enroll 214 patients, which is expected to be completed in 2028."

New P1/2 trial • Oncology

A Novel EGFR x cMET bispecific ADC PRO1286 demonstrated broad antitumor activity and promising tolerability in preclinical models (AACR 2024) - "Small molecule TKIs and amivantamab have been approved for non-small cell lung cancer with relevant actionable genomic alterations (AGA), and monoclonal antibodies offer treatment options for EGFR-expressing head and neck and colorectal cancers without AGA...Sesutecan previously demonstrated promising characteristics in preclinical studies with multiple targets and conferred an encouraging benefit:risk profile in the clinic with a FRα-directed ADC (rinatabart sesutecan)...It may also differentiate from existing EGFR- and/or cMET-targeting agents on broad coverage of EGFR and cMET-expressing tumors with or without the respective AGAs. Effort is under way to advance a DAR optimized molecule to the clinic for the treatment of many EGFR- or cMET-expressing solid tumors."

Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • FOLR1

ProfoundBio to Present Data on Multiple Preclinical Programs From Its Antibody-Drug Conjugate Pipeline at the American Association for Cancer Research Annual Meeting 2024 (PRNewswire) - "ProfoundBio...announced its participation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024....ProfoundBio will showcase its innovative ADC programs through an oral presentation on its EGFR- and cMET-dual targeting ADC PRO1286, a poster presentation detailing preclinical data of a SLITRK6-directed ADC PRO1106, and a late-breaking poster presentation on a CD98-directed ADC developed in partnership with Huahui Health, a clinical-stage biotechnology company."

Late-breaking abstract • Preclinical • Oncology